Eli Lilly and Company $LLY Stock Acquired by Investment Partners LTD.

Key Points

• Investment Partners LTD. increased its Eli Lilly stake by 28.6% in the third quarter to 7,314 shares valued at approximately $8.46 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong quarterly results, with revenue up 38.6% year over year to $24.4 billion and EPS of $7.48, beating analyst expectations. Analysts expect full-year EPS of $35.18, and the company declared a $1.73 quarterly dividend.
• Wall Street remains broadly bullish, with a consensus “Moderate Buy” rating and several analysts raising price targets. However, high valuation, pricing pressure and reliance on GLP-1 drugs remain key risks, while insiders have recently sold shares under pre-arranged trading plans.

Investment Partners LTD. raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 28.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,314 shares of the company's stock after acquiring an additional 1,627 shares during the period. Eli Lilly and Company makes up about 1.3% of Investment Partners LTD.'s investment portfolio, making the stock its 22nd largest position. Investment Partners LTD.'s holdings in Eli Lilly and Company were worth $8,463,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Marshall & Sterling Wealth Advisors Inc. raised its stake in shares of Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company's stock valued at $37,000 after acquiring an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter valued at about $42,000. Foresight Capital Management Advisors Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $49,000. Caitlin John LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $64,000. Finally, IMG Wealth Management Inc. grew its stake in Eli Lilly and Company by 500.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 60 shares of the company's stock worth $72,000 after buying an additional 50 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.1%

LLY opened at $1,415.64 on Monday. The business has a fifty day moving average price of $1,197.72 and a 200 day moving average price of $1,092.57. The stock has a market capitalization of $1.33 trillion, a price-to-earnings ratio of 45.95, a PEG ratio of 1.80 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $834.19 and a 12 month high of $1,449.68. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company's revenue for the quarter was up 38.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $7.02 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 22.46%.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research reports. Wells Fargo & Company upped their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an "overweight" rating in a research report on Friday. Argus increased their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a "buy" rating in a research report on Friday. Sanford C. Bernstein reiterated an "outperform" rating and issued a $1,450.00 target price on shares of Eli Lilly and Company in a research report on Monday, October 26th. Citigroup lifted their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Bank of America reiterated a "buy" rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and an average target price of $1,398.43.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.